Tay-Sachs disease is a rare inherited disorder that progressively destroys neurons in the brain and spinal cord which typically begins during infancy. Tay-Sachs disease is caused by a mutation in the HEXA gene and it is inherited in an autosomal recessive pattern. Tay-Sachs disease is also called Gangliosidosis (GM2) type 1 or Hexosaminidase A deficiency and only 1 in 300 people is a carrier for Tay-Sachs disease. There is no cure for Tay-Sachs disease, however, treatment includes targeting and controlling some of the symptoms - such as providing anticonvulsants to control seizures and proper nutrition and hydration and other comfort measures. Age of death for infants who contract Tay-Sachs disease in typically between 2 and 4 years. Tay-Sachs disease is rare in the general population and the genetic mutations that cause this disease are more common in people of Ashkenazi (eastern and central European) Jewish heritage than in those with other backgrounds.
Tay-sachs Disease Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Tay-sachs Disease below!
For more information on how to use Laverne, please read the How to Guide.
We have 1142 products for the study of Tay-sachs Disease that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Tay-sachs Disease is also known as tay-sachs disease, hexosaminidase a deficiency, tsd, hexa deficiency, tay sachs disease, hex a deficiency, type 1 hexosaminidase a-deficiency, acute infantile gm2 gangliosidosis, lipidosis, ganglioside, infantile, infantile gm>2< gangliosidosis, tay-sachs disease (disorder), gangliosidoses, gm2, disease, tay-sachs, sphingolipidoses, malnutrition, lipoidosis.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.